FrancophonIA/ELRC3.0 huggingface dataset:
English: Splenectomy should also be considered as a relevant factor when reporting the outcome of somatostatin receptor targeted diagnostics.
Estonian: Somatostatiini retseptoritega seotud diagnostilise protseduuri tulemuste aruandluses tuleks kaaluda asjakohase tegurina ka splenektoomiat.
English: Any woman who has missed a period should be assumed to be pregnant until proven otherwise.
Estonian: Kuni pole teisiti tõestatud, tuleb iga naissoost patsienti, kellel on menstruatsioon vahele jäänud, käsitleda kui rasedat.
English: Assay the vial radioactivity using a suitable radioactivity calibration system and record the result.
Estonian: Mõõtke viaali radioaktiivsust, kasutades sobivat doosikalibraatorit ja kirjutage tulemus üles.
English: m. Assay the vial radioactivity using a suitable radioactivity calibration system and record the result.
Estonian: m. Mõõtke viaali radioaktiivsust, kasutades sobivat doosikalibraatorit ja kirjutage tulemus üles.
English: PHARMACEUTICAL FORM AND CONTENTS Kit for radiopharmaceutical preparation The box contains: - 1 vial of powder - 1 vial of buffer
Estonian: Radiofarmatseutiline komplekt Pakend sisaldab: - 1 pulbri viaal - 1 puhverlahuse viaal
English: Renal impairment / Hepatic impairment The safety and efficacy of gallium (68Ga) edotreotide have not been studied in patients with renal or hepatic impairment.
Estonian: Neeru-/maksapuudulikkus Gallium (68Ga)-edotreotiidi ohutust ja efektiivsust neeru-/maksapuudulikkusega patsientidel ei ole uuritud.
English: Storage of radiopharmaceuticals should be in accordance with national regulation on radioactive materials.
Estonian: Radiofarmatseutilisi preparaate tuleks säilitada kooskõlas radioaktiivseid aineid käsitlevate riiklike õigusaktidega.
English: Gallium (68Ga) edotreotide contains a small amount of radioactivity.
Estonian: Gallium (68Ga)-edotreotiid on vähesel määral radioaktiivne.
English: Recommended method for determining labelling efficiency of gallium (68Ga) edotreotide:
Estonian: Soovituslik meetod gallium (68Ga)-edotreotiidi radiomärgistamise tõhususe määramiseks.
English: • One vial of powder for solution for injection: 10 ml Type I glass vial closed with a bromobutyl rubber stopper and sealed with a flip-off cap. Each vial contains 40 micrograms of edotreotide.
Estonian: • Ühte süstelahuse pulbri viaali: 10 ml I tüüpi klaasviaali, mis on suletud bromobutüülkummist punnkorgiga ja eemaldatava kattega.
English: After radiolabelling, the solution obtained also contains, as excipient, hydrochloric acid from the generator eluate.
Estonian: Pärast radiomärgistamist sisaldab saadud lahus abiainena ka vesinikkloriidhapet (generaatori eluaadist).
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS POWDER VIAL
Estonian: MINIMAALSED ANDMED, MIS PEAVAD OLEMA VÄIKESEL VAHETUL SISEPAKENDIL
English: MARKETING AUTHORISATION HOLDER Advanced Accelerator Applications 20 rue Diesel
Estonian: MÜÜGILOA HOIDJA Advanced Accelerator Applications 20 rue Diesel
English: Imaging acquisition start time and duration should be adapted according to the equipment used, the patient and the tumour characteristics in order to obtain the best image quality possible.
Estonian: Parima pildikvaliteedi saavutamiseks tuleks pildihõive algust ja kestust kohandada arvestades kasutatavat seadmestikku ning patsiendi ja tuumori seisundit.
English: monograph 2464 Gallium (68Ga) chloride solution for radiolabelling and that, in addition, is sterile and has been tested for compatibility with SomaKit TOC.
Estonian: See on mõeldud radiomärgistamiseks gallium (68Ga)-kloriidi lahusega, mis vastab Euroopa farmakopöa monograafia 2464 Gallium (68Ga) chloride solution for radiolabelling (Gallium (68Ga)-kloriidi lahus radiomärgistamiseks) nõuetele, ja on steriilne ning selle ühilduvust SomaKit TOC-iga on testitud.
English: About 50 minutes after intravenous administration, gallium (68Ga) edotreotide accumulation shows plateauing in all organs.
Estonian: Umbes 50 minutit pärast intravenoosset manustamist stabiliseerub gallium (68Ga)-edotreotiidi seondumine kõigis organites.
English: METHOD AND ROUTE(S) OF ADMINISTRATION To be radiolabelled with the reaction buffer and a solution of Gallium-68 (68Ga) in HCl provided by a germanium (68Ge)/gallium (68Ga) generator.
Estonian: Radiomärgistada puhverlahuse ja gallium-68 (68Ga)-vesinikkloriidi lahusega, mille saab germaaniumi (68Ge) / galliumi (68Ga) generaatori abil.
English: If you have been given more SomaKit TOC than you should An overdose is unlikely because you will only receive a single dose under controlled conditions by the nuclear medicine doctor supervising the procedure.
Estonian: Üleannustamine on ebatõenäoline, sest protseduur toimub kontrollitud tingimustes ja selle eest vastutav nukleaarmeditsiini arst manustab teile ühekordse annuse.
English: Labelling efficiency
Estonian: Kvaliteedikontroll
English: Acceptance Criteria Method
Estonian: Sobivuse kriteeriumid
English: Finally remove the 0.2 µm sterile vent filter and move the vial to the hole of the dry bath at 95°C, using a plier.
Estonian: Lõpuks eemaldage 0,2 µm steriilne õhutusfilter ja liigutage viaal tangide abil 95 °C kuivtermoblokki.
English: Acceptance Criteria Method colloidal gallium-68 species Labelling efficiency % Free gallium-68
Estonian: Märgistamise tõhusus Vaba gallium-68 (%)
English: Connect Vial 1 through the 0.2 µm sterile vent filter to a vacuum vial or to a pump to start the elution.
Estonian: Elueerimise alustamiseks ühendage viaal 1 steriilse 0,2 µm õhutusfiltri kaudu vaakumviaali või pumbaga.
English: (68 min), the biological half-life will have little impact on the effective half-life of the product which then would be expected to be somewhat less than 68 minutes.
Estonian: Kuna eritumise kiirus on oluliselt väiksem kui galliumi (68Ga) füüsikaline poolestusaeg (68 min), mõjutab bioloogiline poolestusaeg ravimpreparaadi efektiivset poolestusaega vähe, mis on seega eeldatavalt väiksem kui 68 minutit.
English: The organs with high physiological uptake of gallium (68Ga) edotreotide include spleen, kidneys, liver, pituitary gland, thyroid gland and adrenals.
Estonian: Organid, mis omastavad gallium (68Ga)-edotreotiidi füsioloogiliselt kõige kergemini, on põrn, neerud, maks, ajuripats, kilpnääre ja neerupealised.
English: Thus, in patients with GEP-NET and Cushing syndrome, normalisation of hypercortisolism should be suggested before performing PET with gallium (68Ga)
Estonian: Seega tuleks gastroenteropankreaatiliste neuroendokriintuumorite (GEP-NET) ja Cushingi sündroomiga patsientidel enne gallium (68Ga)-edotreotiidiga PET-uuringu teostamist hüperkortisolism normaliseerida.
English: Lesion-detection rate was 75% (3/4) in the subgroup of patients with unknown primary tumour site of the prospective study of Frilling et al. 2010.
Estonian: Frillingu jt (2010) prospektiivses uuringus oli lesioonide leiuprotsent teadmata paikmega primaartuumoriga patsientide alamrühmas 75 % (3/4).
English: However, lesions of GEP-NET not expressing sufficient density of somatostatin receptors cannot be visualised with gallium (68Ga) edotreotide.
Estonian: Kui aga gastroenteropankreaatiliste neuroendokriintuumorite (GEP NET) lesioonides pole somatostatiini retseptorite tihedus piisav, ei saa neid gallium (68Ga)-edotreotiidiga visualiseerida.
English: (70%) and discrepancies in 14 patients (30%) presenting 9 with progressive disease and 5 with remission.
Estonian: Gallium (68Ga)-edotreotiidi PET- ja KT-uuringute tulemused olid kooskõlas 32 patsiendil (70 %), lahknevusi esines 14 patsiendil (30 %), neist 9 progresseeruva haigusega ja 5 remissioonis.
English: Close contact with infants should be restricted during the initial 8 hours following injection.
Estonian: Vahetu kokkupuude imikutega peaks olema keelatud 8 tundi pärast süstimist.
English: Therefore, when treating patients with somatostatin analogues, it is preferable to perform imaging with gallium (68Ga) edotreotide the day(s) preceding the next administration of a somatostatin analogue.
Estonian: Seega tuleks juhul, kui patsienti ravitakse somatostatiini analoogidega, teostada gallium (68Ga)-edotreotiidiga pildindus somatostatiini analoogi manustamisele eelneva(te)l päeva(de)l.
English: Gallium (68Ga) edotreotide solution is stable up to 4 hours after preparation.
Estonian: Radiomärgistamise protseduur Galli Ad generaatorit kasutades Gallium (68Ga)-edotreotiidi lahus on stabiilne kuni 4 tundi pärast valmistamist.
English: Flip off cap from the Vial 2 (Reaction buffer) and swab the top of the vial closure with an appropriate antiseptic to disinfect the surface, and then allow the stopper to dry.
Estonian: Eemaldage viaali 2 (puhverlahuse) kate ja desinfitseerige viaali sulgur sobiva antiseptikuga ning laske sellel kuivada.
English: Connect the Vial 1 to the outlet line of the generator by pushing the needle through the rubber septum.
Estonian: Ühendage viaal 1 generaatori väljavoolutoruga, surudes nõela läbi kummist korgi.
English: Data supporting efficacy of gallium (68Ga) edotreotide for predicting and monitoring of therapeutic response to peptide receptor radionuclide therapy (PRRT) in histologically confirmed metastatic NET are limited (see section 5.1).
Estonian: Gallium (68Ga)-edotreotiidi kliinilist efektiivsust histoloogiliselt kinnitatud metastaatilise neuroendokriintuumori (NET) peptiidretseptorite radionukliidteraapia (PRRT) ravivastuse prognostilise ja jälgimismeetodina kasutamisel toetavad andmed on piiratud (vt lõik 5.1).
English: The following authorised generators have shown to be compatible with SomaKit TOC:
Estonian: SomaKit TOC ühildub järgnevate generaatoritega:
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION SomaKit TOC
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) SomaKit TOC
English: One vial of powder contains 40 µg of edotreotide.
Estonian: Üks pulbri viaal sisaldab 40 mikrogrammi edotreotiidi.
English: • One vial of buffer: 10 ml cyclic olefin polymer vial closed with a teflon stopper and sealed with a flip-off cap. Each vial contains 1 ml of reaction buffer.
Estonian: • Ühte viaali puhverlahusega: 10 ml tsüklilisest olefiinpolümeerist viaali, mis on suletud teflonist punnkorgiga ja eemaldatava kattega.
English: Organ uptake The organ with the highest physiological uptake of gallium (68Ga) edotreotide is the spleen, followed by the kidneys.
Estonian: Füsioloogiliselt kõige paremini gallium (68Ga)-edotreotiidi omastav organ on põrn, millele järgnevad neerud.
English: Depending on the time when you administer the injection, the content of sodium may in some cases be greater than 1 mmol.
Estonian: Olenevalt süstitava ravimi manustamise ajast võib naatriumisisaldus olla teatud juhtudel suurem kui 1 mmol. Seda tuleb arvestada juhul, kui patsient on vähese naatriumisisaldusega dieedil.
English: At the time of administration, the product must be aseptically withdrawn and the radioprotection standards must be followed.
Estonian: Manustamise ajal tuleb järgida kiirguskaitse standardeid ja tõmmata ravimpreparaat süstlasse aseptiliselt.
English: SomaKit TOC contains sodium
Estonian: SomaKit TOC sisaldab naatriumi
English: Withdraw the syringe and the 0.2 µm sterile vent filter and move the vial to the hole of the dry bath at 95°C, using a plier.
Estonian: Tõmmake süstal ja steriilne 0,2 µm õhufilter välja ning liigutage viaal tangide abil 95 °C kuivtermoblokki.
English: Flip off cap from the vial of powder and swab the top of the vial closure with an appropriate antiseptic to disinfect the surface, and then allow the stopper to dry.
Estonian: Eemaldage pulbri viaali kate ning desinfitseerige viaali sulgur sobiva antiseptikuga ja laske sellel kuivada.
English: However, it is recommended that the vial be prepared as instructed and used for a single patient dose, based on the activity to be injected; any remaining material should be discarded after radiolabelling and use.
Estonian: Siiski on soovitav viaali ettevalmistamisel jälgida juhiseid ning kasutada seda ühe patsiendi annusena, arvestades süstimiseks vajalikku aktiivsust.
English: An increased uptake of gallium (68Ga) edotreotide is not specific for GEP-NET.
Estonian: Gallium (68Ga)-edotreotiidi suurem omastamine ei ole eriomane ainult gastroenteropankreaatilistele neuroendokriintuumoritele (GEP-NET).
English: Before administration of SomaKit TOC
Estonian: Enne SomaKit TOC-i manustamist
English: STATEMENT OF ACTIVE SUBSTANCE(S) One vial of powder contains 40 micrograms of edotreotide
Estonian: TOIMEAINE(TE) SISALDUS Üks pulbriviaal sisaldab 40 mikrogrammi edotreotiidi.
English: Store the vial containing the gallium (68Ga) edotreotide solution below 25°C until use.
Estonian: Säilitage gallium (68Ga)-edotreotiidi lahust sisaldavat viaali kasutamiseni temperatuuril kuni 25°C.
English: How SomaKit TOC is used
Estonian: Kuidas SomaKit TOC-i kasutada
English: Each 40 microgram vial contains an excess of product.
Estonian: Iga 40 mikrogrammi viaal sisaldab ravimit rohkem kui vaja.
English: d. Scan the ITLC with a radiometric ITLC scanner e. The retention factor (Rf) specifications are as follows: Not complexed gallium (68Ga) = 0 to 0.1 gallium (68Ga) edotreotide = 0.8 to 1
Estonian: Mittekomplekseeritud gallium (68Ga) = 0 kuni 0,1 gallium (68Ga)-edotreotiid = 0,8 kuni 1
English: b. Apply a drop of the gallium (68Ga) edotreotide solution on a pencil line 1 cm from the bottom of the ITLC strip.
Estonian: b. Tilgutage tilk gallium (68Ga)-edotreotiidi pliiatsijoonele, mis on 1 cm ITLC-riba alumisest servast.
English: At the chemical concentrations used for diagnostic examinations, gallium (68Ga) edotreotide does not appear to have any clinically relevant pharmacodynamic effect.
Estonian: Farmakodünaamilised toimed Diagnostilistel uuringutel kasutatud keemilistes kontsentratsioonides ei paista gallium (68Ga)
English: Mechanism of action Gallium (68Ga) edotreotide binds to somatostatin receptors.
Estonian: Toimemehhanism Gallium (68Ga)-edotreotiid seondub somatostatiini retseptoritega.
English: No radioactive metabolites were detected in serum within 4 hours after intravenous injection of gallium (68Ga) edotreotide.
Estonian: 4 tundi pärast gallium (68Ga)-edotreotiidi intravenoosset süstimist ei leitud seerumist ühtki radioaktiivset metaboliiti.
English: Data available on clinical efficacy of gallium (68Ga) edotreotide for the indication of predicting and monitoring of therapeutic response to peptide receptor radionuclide therapy (PRRT) in histologically confirmed metastatic NET are limited.
Estonian: Andmed gallium (68Ga)-edotreotiidi kliinilise efektiivsuse kohta histoloogiliselt kinnitatud metastaatilise neuroendokriintuumori (NET) peptiidretseptorite radionukliidteraapia (PRRT) ravivastuse prognostilise ja jälgimismeetodina on piiratud.
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION SomaKit TOC 40 micrograms solution for injection Gallium (68Ga) edotreotide
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) SomaKit TOC 40 mikrogrammi süstelahus Gallium (68Ga)-edotreotiid
English: pH-indicator strips
Estonian: pH-testribad
English: The safety and efficacy of gallium (68Ga) edotreotide has not been established in paediatric populations, where the effective dose might be different than in adults.
Estonian: Gallium (68Ga)-edotreotiidi ohutus ja efektiivsus lastel (kelle efektiivdoos võib täiskasvanute omast erineda) ei ole veel tõestatud.
English: The three remaining retrospective studies recruited small samples (ranging from 20 to 28 GEP-NET patients or those with cancer of unknown origin) and found that semiquantitative uptake in the pre-PRRT gallium (68Ga)
Estonian: Kolme ülejäänud retrospektiivsesse uuringusse värvati väikesed valimid (vahemikus 20...28 gastroenteropankreaatilise neuroendokriintuumoriga (GEP-NET) või teadmata päritoluga vähkkasvajaga patsienti) ja leiti, et PRRT-eelne gallium (68Ga)-edotreotiidiga tehtud poolkvantitatiivse omastamisega PET-uuring korreleerus tuumori omastatud annustega süstitud aktiivsuse kohta järgnevas esimeses ravitsüklis, erines pärast kolme PRRT-tsüklit ravile reageerivates ja mittereageerivates lesioonides ning aitas eristada maksametastaase normaalsest maksakoest.
English: Ga) edotreotide to structures or receptors other than SSTR remains unknown.
Estonian: Lisaks jääb teadmata gallium (68Ga)-edotreotiidi in vivo seondumine muude struktuuride või retseptoritega peale SSTR-i retseptorite.
English: In the study of Lee et al. 2015 in 13 GEP-NET patients, a total of 35 positive lesions were detected in 10 patients on either gallium (68Ga) edotreotide PET/CT or indium (111In) pentetreotide
Estonian: gastroenteropankreaatilise neuroendokriintuumoriga (GEP-NET) patsiendil tuvastati 10 patsiendil kokku 35 positiivset lesiooni kas gallium (68Ga)-edotreotiidiga tehtud PET/KT-uuringul või indium (111In)-pentetreotiidiga tehtud SPECT/KT-uuringul, kolmel patsiendil ei leitud positiivseid lesioone kummagi kuvameetodiga.
English: The gallium (68Ga) edotreotide solution for intravenous injection must be prepared according to aseptic procedure, local regulation and the following instructions.
Estonian: Intravenoosselt süstitav gallium (68Ga)-edotreotiidi lahus tuleb valmistada, järgides aseptilisi nõudeid,
English: In GEP-NET, a more intense gallium (68Ga) edotreotide uptake than normal background is a consistent finding.
Estonian: Järjepidevalt on leitud, et gastroenteropankreaatilises neuroendokriintuumoris (GEP-NET) toimub normaalsest taustast intensiivsem gallium (68Ga)-edotreotiidi omastamine.
English: OTHER Do not store above 25ºC
Estonian: MUU Hoida temperatuuril kuni 25ºC.
English: For the detection of the primary GEP-NET site in case of rising levels of a relevant biochemical tumour marker or in case of proven NET metastasis, patient-based sensitivity and specificity of gallium (68Ga) edotreotide PET were 100% (4/4) and 89% (8/9), respectively, in the prospective study of Gabriel et al. 2007.
Estonian: edotreotiidiga PET-uuringu patsiendipõhine tundlikkus ja spetsiifilisus primaarse gastroenteropankreaatilise neuroendokriintuumori (GEP-NET) paikme tuvastamisel vastavalt 100% (4/4) ja 89 % (8/9).
English: Quality control Table 2: Specifications of the gallium (68Ga) edotreotide
Estonian: Radiomärgistatud ravimpreparaadi spetsifikatsioonid (gallium (68Ga)-edotreotiid) Test
English: With a low dead space 1 ml sterile syringe carefully withdraw 100 µl and keep the reaction buffer in syringe for step “g”.
Estonian: Kasutage steriilset väikesemahulist 1 ml süstalt, et tõmmata ettevaatlikult 100 µl kogus süstlasse.
English: NAME OF THE MEDICINAL PRODUCT SomaKit TOC 40 micrograms kit for radiopharmaceutical preparation
Estonian: RAVIMPREPARAADI NIMETUS SomaKit TOC 40 mikrogrammi radiofarmatseutiline komplekt
English: How SomaKit TOC is stored
Estonian: Kuidas SomaKit TOC-i säilitada
English: NAME OF THE MEDICINAL PRODUCT SomaKit TOC 40 micrograms kit for radiopharmaceutical preparation edotreotide
Estonian: RAVIMPREPARAADI NIMETUS SomaKit TOC 40 mikrogrammi radiofarmatseutiline komplekt edotreotiid
English: With a low dead space 1 ml sterile syringe carefully withdraw 0.5 ml reaction buffer, and keep the reaction buffer in syringe for step “i”.
Estonian: Kasutage steriilset väikesemahulist 1 ml süstalt, et tõmmata ettevaatlikult 0,5 ml puhverlahust süstlasse.
English: Kidneys
Estonian: Eritumine
English: d. Scan the ITLC with a radiometric ITLC scanner The retention factor (Rf) specifications are as follows: gallium (68Ga) edotreotide = 0.1 to
Estonian: Retentsioonifaktori (Rf) spetsifikatsioonid on järgmised.68Ga)-edotreotiid = 0,1 kuni 0,2
English: Concomitant use of somatostatin analogues It is preferable to perform imaging with gallium (68Ga) edotreotide the day(s) before the next administration of a somatostatin analogue.
Estonian: Somatostatiini analoogide samaaegne kasutus Gallium (68Ga)-edotreotiidiga pildindus on soovitatav teostada somatostatiini analoogi manustamisele eelneva(te)l päeva(de)l. Vt lõik 4.5.
English: A lesion detection rate of 100% (40/40) versus 85% (34/40) was observed in the study of Hofmann et al. 2001 recruiting patients with histologically proven bronchial (n=2) or midgut (n=6) NETs.
Estonian: (n = 2) või kesksoole (n = 6) histoloogiliselt tõendatud neuroendokriintuumoriga (NET) patsiendid, oli lesioonide leiuprotsent 100% (40 / 40) versus 85% (34 / 40).
English: However, after gallium (68Ga) chloride solution is added, adequate shielding of the final preparation must be maintained.
Estonian: Ga)-kloriidi lahuse lisamist tuleb aga valmispreparaadi eest kaitsmiseks kasutada sobivaid kiirguskaitsevahendeid.
English: What you need to know before SomaKit TOC is used 3.
Estonian: 1. Mis ravim on SomaKit TOC ja milleks seda kasutatakse 2. Mida on vaja teada enne SomaKit TOC-i kasutamist 3.
English: Table 1: Dosimetry of gallium (68Ga) edotreotide
Estonian: Gallium (68Ga)-edotreotiid dosimeetria tulemused
English: Image acquisition
Estonian: Pildihõive
English: A schematic representation of the radiolabelling procedure is shown in
Estonian: Radiomärgistamise protseduuri skeem on näidatud joonisel 1.
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION SomaKit TOC 40 micrograms powder for solution for injection edotreotide
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) SomaKit TOC 40 mikrogrammi süstelahuse pulber edotreotiid
English: SomaKit TOC 40 micrograms kit for radiopharmaceutical preparation Edotreotide
Estonian: Pakendi infoleht: teave patsiendile SomaKit TOC 40 mikrogrammi radiofarmatseutiline komplekt Edotreotiid
English: See section 4.5.
Estonian: Võimalikud kõrvaltoimed 5.
English: Breastfeeding
Estonian: Sipelghape
English: Non-clinical data did not reveal any special hazard for gallium (68Ga) edotreotide in humans.
Estonian: Gallium (68Ga)-edotreotiidi mittekliinilised uuringud ei ole näidanud kahjulikku toimet inimesele.
English: However, the risk of transmission is still possible.
Estonian: Kuid ülekandumise risk on siiski võimalik.
English: refers to the last day of that month.
Estonian: Kõlblikkusaeg viitab kuu viimasele päevale.
English: Austria, Bulgaria, Cyprus, Czech Republic, Estonia, Finland, Germany, Greece, Iceland, Ireland, Latvia, Lithuania, Malta, Norway, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom: Valtrex
Estonian: Austria, Bulgaaria, Küpros, Tšehhi Vabariik, Eesti, Soome, Saksamaa, Kreeka, Island, Iirima, Läti, Leedu, Malta, Norra, Portugal, Rumeenia, Slovakkia, Sloveenia, Hispaania, Rootsi, Ühendkuningriik: Valtrex
English: Adequate hydration should be maintained.
Estonian: Tuleb säilitada adekvaatne hüdreeritus.
English: 75014 PARIS France
Estonian: 75014 PARIS
English: Valtrex is not usually harmful, unless you take too much over several days.
Estonian: Valtrex ei ole tavaliselt kahjulik, välja arvatud juhul, kui te võtate seda mitmeid päevi liiga palju.
English: Pregnant women
Estonian: Rasedad naised
English: 30 to 49 10 to 29
Estonian: 30 kuni 49 10 kuni 29
English: Conditions you need to look out for
Estonian: Seisundid, mida te peate oskama jälgida
English: Recommendations for use also show differences.
Estonian: Erinevusi esineb ka kasutamissoovitustes.
English: 105 Reykjavík, Iceland
Estonian: 105 Reykjavík, Island
English: A recent metaanalysis (Lebrun-Vignes, 2007) provided additional supportive data for this indication.
Estonian: Ka hiljutine metaanalüüs (Lebrun-Vignes, 2007) andis täiendavaid andmeid selle näidustuse kinnituseks.
English: 169 29 Solna, Sweden
Estonian: 169 29 Solna, Rootsi
English: • seeing or hearing things that aren't there (hallucinations)
Estonian: • olematute asjade kuulmine või nägemine (hallutsinatsioonid)
English: Dosing should begin as early as possible.
Estonian: Annustamisega tuleb alustada niipea kui võimalik.
English: The duration of treatment will usually be 90 days, but may need to be extended in high-risk patients.
Estonian: Tavaliselt on ravikuuri pikkus 90 päeva, kuid seda võib riskipatsientidel pikendada.
English: This is important to prevent you passing the infection on to others.
Estonian: See on oluline, et vältida teie infektsiooni edasikandumist teistele isikutele.
English: • you are over 65 years of age
Estonian: • kui te olete vanem kui 65-eluaastat.